About this policy
The comment period for the MolDX: Oncotype DX AR-V7 Nucleus Detect for Men with Metastatic Castrate Resistant Prostate Cancer (MCRPC) DL37744 began on 06/07/2018 and ended on 08/14/2018. Comments were received from the provider community. The notice period begins on 1/15/2019 and ends 3/1/2019. The LCD becomes effective on 3/2/2019.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.